Development of polymeric systems for cabazitaxel release

Cabazitaxel (CTZ) is a chemotherapy drug used to treat mCRPC patients. Bacterial cellulose (BC) has been combined with molecularly imprinted polymer (MIP) for anticancer drug delivery with controlled release. On surface-modified bacterial cellulose nanofibers, composite molecularly imprinted nanofibers were prepared by in-situ graft polymerization of methacrylic acid as the monomer, N, N'-Methylenebisacrylamide as the crosslinker, and Cabazitaxel as the template molecule. Cabazitaxel-imprinted polymers were fabricated onto bacterial cellulose nanofibers, resulting in the formation of composite BC nanofibers. Consequently, the composite nanofibers incorporated with cabazitaxel imprinted polymers were attained and fabricated. The in-vitro drug release tests were conducted to evaluate the release performance of the resultant composite nanofibers at varying temperatures of 25, 37, and 40 °C, concentrations of 0.5, 1, 2, 3, and 4 mg/mL, and different pH values (5.5, 6, 7, 7.4, and 8). The application of MIP-BC in medicine and pharmaceutics may be of great interest due to the simplicity of preparing the drug delivery system without synthetic MIP.